Novartis pulls Rasilamlo in Germany citing new pharma pricing law
This article was originally published in Scrip
Executive Summary
Novartis has stopped marketing Rasilamlo (aliskiren plus amlodipine) in Germany because the authorities there have requested excessive and unavailable data under the new pricing regulations, the company has told Scrip.